Abstract:
:Quantum dots (QDs) are luminescent nanocrystals with rich surface chemistry and unique optical properties that make them useful as probes or carriers for traceable targeted delivery and therapy applications. QDs can be functionalized to target specific cells or tissues by conjugating them with targeting ligands. Recent advancement in making biocompatible QD formulations has made these nanocrystals suitable for in vivo applications. This review provides an overview of the preparation of QDs and their use as probes or carriers for traceable, targeted therapy of diseases in vitro and in vivo. More specifically, recent advances in the integration of QDs with drug formulations for therapy and their potential toxicity in vitro and in vivo are highlighted. The current findings and challenges for optimizing QD/drug formulations with respect to optimal size and stability, short-term and long-term toxicity, and in vivo applications are described. Lastly, we attempt to predict key trends in QD/drug formulation development over the next few years and highlight areas of therapy where their use may provide breakthrough results in the near future.
journal_name
Theranosticsjournal_title
Theranosticsauthors
Yong KT,Wang Y,Roy I,Rui H,Swihart MT,Law WC,Kwak SK,Ye L,Liu J,Mahajan SD,Reynolds JLdoi
10.7150/thno.3692subject
Has Abstractpub_date
2012-01-01 00:00:00pages
681-94issue
7issn
1838-7640pii
thnov02p0681journal_volume
2pub_type
杂志文章相关文献
Theranostics文献大全abstract::Using non-covalent interactions between nucleic acids (DNA, siRNA, miRNA, and mRNA) with peptides or nucleopeptides is a promising strategy to construct supramolecular assemblies for gene delivery and therapy. Comparing to conventional strategies for gene delivery, the assemblies of peptides or nucleopeptides provide ...
journal_title:Theranostics
pub_type: 杂志文章,评审
doi:10.7150/thno.31854
更新日期:2019-05-18 00:00:00
abstract::Photodynamic therapy (PDT) is an emerging theranostic modality for various cancers and diseases. The focus of this study was the development of tumor-targeting albumin nanoparticles containing photosensitizers for efficient PDT. To produce tumor-targeting albumin nanoparticles, the hydrophobic photosensitizer, chlorin...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno/v01p0230
更新日期:2011-04-06 00:00:00
abstract::The relatively new field of nanotheranostics combines the advantages of in vivo diagnosis with the ability to administer treatment through a single nano-sized carrier, offering new opportunities for cancer diagnosis and therapy. Nanotheranostics has facilitated the development of nanomedicine through direct visualizat...
journal_title:Theranostics
pub_type: 杂志文章,评审
doi:10.7150/thno.4381
更新日期:2012-01-01 00:00:00
abstract::Aplastic anemia (AA) is characterized as hypoplasia of bone marrow hematopoietic cells and hematopenia of peripheral blood cells. Though the supplement of exogenous erythropoietin (EPO) has been clinically approved for AA treatment, the side-effects hinder its further application. Here a robust treatment for AA induce...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.46794
更新日期:2020-05-23 00:00:00
abstract::Pretargeting is a multi-step process that first has an unlabeled bispecific antibody (bsMAb) localize within a tumor by virtue of its anti-tumor binding site(s) before administering a small, fast-clearing radiolabeled compound that then attaches to the other portion of the bsMAb. The compound's rapid clearance signifi...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.3582
更新日期:2012-01-01 00:00:00
abstract::Circulating tumor cells (CTCs) have shown promising potential as liquid biopsies that facilitate early detection, prognosis, therapeutic target selection and monitoring treatment response. CTCs in most cancer patients are low in abundance and heterogeneous in morphological and phenotypic profiles, which complicate the...
journal_title:Theranostics
pub_type: 杂志文章,评审
doi:10.7150/thno.18588
更新日期:2017-06-25 00:00:00
abstract::Osteoarthritis (OA) is a rheumatic disease leading to chronic pain and disability with no effective treatment available. Recently, allogeneic human mesenchymal stromal/stem cells (MSC) entered clinical trials as a novel therapy for OA. Increasing evidence suggests that therapeutic efficacy of MSC depends on paracrine ...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.20746
更新日期:2018-01-01 00:00:00
abstract::A major challenge in photodynamic therapy (PDT) is the development of new tumor-targeting photosensitizers. The tumor-specific activation is considered to be an effective strategy for designing these photosensitizers. Herein, we describe a novel tumor-pH-responsive supramolecular photosensitizer, LDH-ZnPcS8, which is ...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.18861
更新日期:2017-07-07 00:00:00
abstract::Because of the unparalleled efficiency and universal utility in treating a variety of disease types, siRNA agents have evolved as the future drug-of-choice. Yet, the inability of the polyanionic siRNA macromolecules to cross the cell membrane remains as the bottleneck of possible clinical applications. With the cell p...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.19863
更新日期:2017-06-25 00:00:00
abstract::Purpose: Positron emission tomography (PET) imaging of apoptosis is very important for early evaluation of tumor therapeutic efficacy. A stimuli-responsive probe based on the peptide sequence Asp-Glu-Val-Asp (DEVD), [18F]DEVD-Cys(StBu)-PPG(CBT)-AmBF3 ([18F]1), for PET imaging of tumor apoptosis was designed and prepar...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.35084
更新日期:2019-09-21 00:00:00
abstract::The therapeutic efficacy of fluorescence image-guided tumor surgery and photodynamic therapy (PDT) is impaired by the penetration depth limitation, low signal-to-noise ratio of traditional first near-infrared window (NIR I) fluorescence and the hypoxic tumor microenvironment. Here, a "red blood cell-based multimodal p...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.29817
更新日期:2019-01-01 00:00:00
abstract::5-Fluorouracil (5-FU) combined with radiotherapy is a common treatment strategy to treat human cancers, but the underlying mechanisms of this combination treatment remain unclear. Here, we report that NAD+-dependent deacetylase sirtuin-7 (SIRT7) protein levels were decreased due to 5-FU exposure rendering colorectal c...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.18804
更新日期:2017-03-22 00:00:00
abstract::Nanobubble (NB), which simultaneously enhances ultrasound (US) images and access therapeutic platforms, is required for future cancer treatment. Methods: We designed a theranostic agent for novel cancer treatment by using an NB-encapsulated hybrid nanosystem that can be monitored by US and fluorescent imaging and acti...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.38684
更新日期:2020-01-01 00:00:00
abstract::Purpose: Cancer immunotherapy depends on a systemic immune response, but the basic underlying mechanisms are still largely unknown. Despite the very successful and widespread use of checkpoint inhibitors in the clinic, the majority of cancer patients do not benefit from this type of treatment. In this translational st...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.35989
更新日期:2020-01-01 00:00:00
abstract::Protein therapeutics is playing an increasingly critical role in treatment of human diseases. However, current vectors are captured by the digestive endo-lysosomal system, which results in an extremely low fraction (<2%) of protein being released in the cytoplasm. This paper reports a drug-delivering-drug platform (HA...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.23804
更新日期:2018-06-06 00:00:00
abstract::Biological cancer therapies, such as oncolytic, or replication-selective viruses have advantages over traditional therapeutics as they can employ multiple different mechanisms to target and destroy cancers (including direct cell lysis, immune activation and vascular collapse). This has led to their rapid recent clinic...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.3724
更新日期:2012-01-01 00:00:00
abstract::Granzyme B (GrB) is an essential cytotoxic effector in cancer immunotherapy as it can be a potential biomarker to predict the efficacy of immunotherapies including checkpoint inhibitors. Monitoring the Granzyme B activity in cells would help determine a patient's clinical response to treatment and lead to better treat...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.37728
更新日期:2020-01-01 00:00:00
abstract::Treatments of high specificity are desirable for cancer therapy. Light-triggered nanotheranostics (LTN) mediated cancer therapy could be one such treatment, as they make it possible to visualize and treat the tumor specifically in a light-controlled manner with a single injection. Because of their great potential in c...
journal_title:Theranostics
pub_type: 杂志文章,评审
doi:10.7150/thno.15217
更新日期:2016-04-27 00:00:00
abstract::The distorted and unique expression of microRNAs (miRNAs) in cancer makes them an attractive source of biomarker. There is much evidence indicating that a panel of miRNAs, termed "miRNA fingerprints", is more specific and informative than an individual miRNA as biomarker. Thus, multiplex assays for simultaneous quanti...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.19113
更新日期:2017-07-08 00:00:00
abstract::Norepinephrine modulates cognitive processes such as working and episodic memory. Pathological changes in norepinephrine and norepinephrine transporter (NET) function and degeneration of the locus coeruleus produce irreversible impairments within the whole norepinephrine system, disrupting cognitive processes. Monitor...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.29740
更新日期:2019-01-01 00:00:00
abstract::Prostate-specific membrane antigen (PSMA) targeted PET has a high detection rate for biochemical recurrence (BCR) of prostate cancer (PCa). Nevertheless, even at high prostate-specific antigen (PSA) levels (> 3 ng/ml), a relevant number of PSMA-PET scans are negative, mainly due to PSMA-negative PCa. Our objective was...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.44584
更新日期:2020-05-15 00:00:00
abstract::Rationale: The overall success rate of prostate cancer (PCa) diagnosis and therapy has been improved over the years. However, genomic and phenotypic heterogeneity remains a major challenge for effective detection and treatment of PCa. Efforts to better classify PCa into functional subtypes and elucidate the molecular ...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.33292
更新日期:2019-05-24 00:00:00
abstract::Background: By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. Accurate imaging of PCa recurrent lymph node metastases (LNM) is crucial for metasta...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.18421
更新日期:2017-04-10 00:00:00
abstract::Background: Metastasis is the major reason for high recurrence rates and poor survival among patients with colorectal cancer (CRC). However, the underlying molecular mechanism of CRC metastasis is unclear. This study aimed to investigate the role of forkhead box K2 (FOXK2), one of the most markedly increased FOX genes...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.31716
更新日期:2019-05-31 00:00:00
abstract::SIRT6, NAD+-dependent deacetylase sirtuin 6, has recently shown to suppress tumor growth in several types of cancer. Colon cancer is a challenging carcinoma associated with high morbidity and death. However, whether SIRT6 play a direct role in colon tumorigenesis and the underlying mechanism are not understood. Method...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.29724
更新日期:2019-04-13 00:00:00
abstract::Intrinsic and acquired resistance to targeted therapies is a significant clinical problem in cancer. We previously showed that resistance to regorafenib, a multi-kinase inhibitor for treating colorectal cancer (CRC) patients, can be caused by mutations in the tumor suppressor FBW7, which block degradation of the pro-s...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.45363
更新日期:2020-07-09 00:00:00
abstract::Rationale: Treating diseases of the brain such as Alzheimer's disease (AD) is challenging as the blood-brain barrier (BBB) effectively restricts access of a large number of potentially useful drugs. A potential solution to this problem is presented by therapeutic ultrasound, a novel treatment modality that can achieve...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.22852
更新日期:2018-04-03 00:00:00
abstract::Resistance to the chemotherapeutic drug 5'-azacytidine (5'-AZA) is a major obstacle in the treatment of patients with acute myeloid leukemia (AML). The uridine-cytidine kinase 1 (UCK1) has an established role in activating 5'-AZA and its protein level is significantly downregulated in patients resistant to the drug. H...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.36503
更新日期:2020-01-01 00:00:00
abstract::Background: Lung cancer has a high mortality rate and is resistant to multiple chemotherapeutics. Natural Borneol (NB) is a monoterpenoid compound that facilitates the bioavailability of drugs. In this study, we investigated the effects of NB on chemosensitivity in the A549 human lung adenocarcinoma cell line and to e...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.45861
更新日期:2020-08-13 00:00:00
abstract::To generate a more efficient in vivo reporter and therapeutic gene, we optimized the coding sequence of the human sodium/iodide symporter (NIS) gene by replacing NIS DNA codons from wild type to new codons having the highest usage in human gene translation. The Codon Adaptation Index (CAI), representing the number of ...
journal_title:Theranostics
pub_type: 杂志文章
doi:10.7150/thno.10062
更新日期:2015-01-01 00:00:00